Network Pharmacology, Molecular Dynamics and In Vitro Assessments of Indigenous Herbal Formulations for Alzheimer's Therapy
Oluwafemi Adeleke Ojo,Omolola Adenike Ajayi-Odoko,Gideon Ampoma Gyebi,Damilare IyinKristi Ayokunle,Akingbolabo Daniel Ogunlakin,Emmanuel Henry Ezenabor,Adesoji Alani Olanrewaju,Oluwatobi Deborah Agbeye,Emmanuel Tope Ogunwale,Damilare Emmanuel Rotimi,Dalia Fouad,Gaber El-Saber Batiha,Oluyomi Stephen Adeyemi
DOI: https://doi.org/10.3390/life14101222
2024-09-25
Life
Abstract:Alzheimer's disease (AD) is an age-associated neurodegenerative condition marked by amyloid plaques, synaptic dysfunction, and neuronal loss. Besides conventional medical care, herbal therapies, both raw and refined, have attracted researchers for their potential therapeutic effects. As a proof-of-concept, our study combined HPLC-DAD analysis of bioactive constituents, network pharmacology, molecular dynamics (MD), molecular docking, post-MD analysis, and experimental verification to investigate the mechanisms of crude drug formulations as a therapeutic strategy for AD. We identified nine bioactive compounds targeting 188 proteins and 1171 AD-associated genes. Using a Venn diagram, we found 47 overlapping targets, forming "herb-compound-target (HCT)" interaction networks and a protein‒protein interaction (PPI) network. Simulations analyzed binding interactions among the three core targets and their compounds. MD assessed the stability of the best-ranked poses and beneficial compounds for each protein. Among the top 22 hub genes, AChE, BChE, and MAO, ranked 10, 14, and 34, respectively, were selected for further analysis. Two tetraherbal formulations, Form A and Form B, showed notable activity against AChE. Form A exhibited significant (p < 0.0001) inhibitory activity (IC50 = 114.842 ± 2.084 μg/mL) compared to Form B (IC50 = 142.829 ± 4.258 μg/mL), though weaker than galantamine (IC50 = 27.950 ± 0.122 μg/mL). Form B had significant inhibitory effects on BChE (IC50 = 655.860 ± 32.812 μg/mL) compared to Form A (IC50 = 679.718 ± 20.656 μg/mL), but lower than galantamine (IC50 = 23.126 ± 0.683 μg/mL). Both forms protected against Fe2+-mediated brain injury by inhibiting MAO. Docking identified quercetin (−10.2 kcal/mol) and myricetin (−10.1 kcal/mol) for AChE; rutin (−10.6 kcal/mol) and quercetin (−9.7 kcal/mol) for BChE; and kaempferol (−9.1 kcal/mol) and quercetin (−8.9 kcal/mol) for MAO. These compounds were thermodynamically stable based on MD analysis. Collectively, the results offer a scientific rationale for the use of these specifically selected medicinal herbs as AD medications.
biology